Article

Mmarketwatch.com on 2018-07-25 23:14

Biogen shares down 9% after Alzheimer's trial results

Wall Street

Related news

MBiogen shares rise 4% before release of Alzheimer's disease trial results marketwatch.com
Wall Street
BBiogen Stock Drops as Results Fall Short. Sales of Alzheimer's Drug Disappoint.3 min read barrons.com
Wall Street
Biogen shares soar as FDA reviewers support Alzheimer's drug Sydney Morning Herald
Wall Street , Massachusetts , Cambridge
Biogen results rise, but miss 1Q forecasts Merced Sun-Star
Germany , Wall Street
MUPDATE: Biogen shares drop 3% on negative update for Alzheimer's disease drug marketwatch.com
FBiogen shares fall on Alzheimer trial results ft.com
Biogen Results Top Expectations wsj.com
Wall Street
MBiogen stock surges 16% as analysts mostly cheer positive results in Alzheimer’s trial marketwatch.com
Mizuho-machi , Phase 2
Biogen down in premarket trading after newest Alzheimer's drug trial results bizjournals.com
MBiogen shares tumble on Alzheimer's candidate data marketwatch.com
Biogen Drug Could Inspire New Hope For Alzheimer's Forbes
Wall Street , Germany , France , Nice , New Hope
MAll eyes will be on Biogen Alzheimer’s results this week — and the stock could swing wildly marketwatch.com
New York , Wall Street , Chicago
Biogen reanalyzes studies, presses ahead on Alzheimer's drug lasvegassun.com
Indianapolis , Wall Street , Mayo Clinic , United States , Japan
Biogen submits US marketing application for Alzheimer's disease drug The Jerusalem Post (JPost.com)
Israel
MBiogen stock declines after stroke trial failure marketwatch.com
Biogen And Eisai Present Positive Results For Experimental Alzheimer's Drug Forbes
Biogen trial drug shows promise in fight against Alzheimer's The Japan Times
Arizona , Phoenix , Switzerland , United States
Biogen releases Alzheimer's early trial data showing significant improvement bizjournals.com
Biogen analysts pounce on 'thin' Alzheimer's trial data bizjournals.com